CT
UTHR icon

Colonial Trust’s United Therapeutics UTHR Stock Holding History

Colonial Trust’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8
Closed -$4.51K – 1186
2026
Q1 		$4.51K Sell
8
-11
-58% -$5.48K ﹤0.01% 870
2025
Q4 		$9.07K Hold
19
– – ﹤0.01% 772
2025
Q3 		$7.8K Sell
19
-6
-24% -$2.02K ﹤0.01% 776
2025
Q2 		$7.12K Buy
25
+2
+9% +$598 ﹤0.01% 788
2025
Q1 		$7.07K Sell
23
-4
-15% -$1.37K ﹤0.01% 788
2024
Q4 		$9.54K Buy
27
+19
+238% +$6.98K ﹤0.01% 949
2024
Q3 		$2.88K Buy
+8
New +$2.7K ﹤0.01% 967
2023
Q4 		– Sell
-26
Closed -$5.87K – 1009
2023
Q3 		$5.87K Buy
+26
New +$5.99K ﹤0.01% 770

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Colonial Trust's UTHR Position: Q2 2026 in Review

Colonial Trust sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 8 shares — an estimated $4.51K sold.

Colonial Trust first reported a position in UTHR in Q3 2023 and held it in 8 quarters. The position peaked at $9.54K in Q4 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Colonial Trust reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Colonial Trust sold 8 United Therapeutics shares in Q2 2026, an estimated $4.51K.
  • Colonial Trust first reported a position in United Therapeutics in Q3 2023 and held it in 8 quarters.
  • Colonial Trust's United Therapeutics position peaked at $9.54K in Q4 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.